
Canopy Growth (CGC) shares have been in a sharp uptrend this week following reports President Donald Trump will reclassify cannabis as a “Schedule III” drug within the next few days.
Additionally, the president is also considering announcing a Medicare pilot program that would let some seniors access cannabis products at a subsidized rate.